Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07364370
NA

Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery

Sponsor: Cairo University

View on ClinicalTrials.gov

Summary

Myopic shift remains a debilitating and unpredictable adverse event following pediatric cataract surgery. While research exploring peripheral myopic defocus for post-cataract surgery myopia prevention shows promising results, the use of multifocal intra-ocular lenses (IOLs) cannot be used liberally in countries with high disease burden and challenged economies due to high price and decreased availability. To date there are no studies evaluating the use of topical atropine for the management of myopic shift following pediatric cataract surgery. The investigators aim to explore the use of 0.05% topical atropine in the prevention and management of myopic shift following pediatric cataract surgery.

Official title: Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery: A Randomized Clinical Trial

Key Details

Gender

All

Age Range

1 Year - 7 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2026-02

Completion Date

2027-12

Last Updated

2026-01-23

Healthy Volunteers

No

Interventions

DRUG

Atropine Eye drops

Atropine eye drops, 0.05%, will be given following IOL implantation for a period of 12 months.

Locations (1)

Cairo University

Cairo, Egypt